2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Insulin Receptor
  5. Insulin Receptor Antagonist

Insulin Receptor Antagonist

Insulin Receptor Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-P2093B
    S961 acetate
    		Antagonist 99.52%
    S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-P2542
    GIP (3-42), human
    		Antagonist 98.24%
    GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo.
  • HY-P2093A
    S961 TFA
    		Antagonist
    S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-P2093
    S961
    		Antagonist
    S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-15481
    KU14R
    		Antagonist
    KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.